This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 0.00% and -48.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
IGM Biosciences (IGMS) delivered earnings and revenue surprises of +626.67% and +4,388.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 61.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Tango Therapeutics (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 75.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
by Zacks Equity Research
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -5.88% and 13.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -11.71% and 51.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -9.38% and 47.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -5.88% and 85.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 81.25% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 20.59% and 44.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 29.41% and 169.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
by Zacks Equity Research
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -12.90% and 9.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of -14.29% and 30.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -2.17% and 79.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
by Ekta Bagri
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
Wall Street Analysts Predict an 110.53% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 110.5% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.